Trial Profile
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Capecitabine
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BACCI
- 15 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 10 May 2023 Planned End Date changed from 27 Mar 2023 to 1 Jul 2023.
- 13 Apr 2021 Planned End Date changed from 26 Mar 2021 to 27 Mar 2023.